Conference Day Two: Wednesday, July 31
8:00 am Coffee & Networking
8:45 am Chair’s Opening Remarks
Clinical Advances in Liquid & Solid Tumors of Gamma Delta T Cell Therapies in 2024
9:00 am Clinical Overview: Gamma Delta-Based Cell Therapy in Cancer & Autoimmune Diseases
Synopsis
- Adicet pipeline of gamma-delta T cell therapies
- Clinical data in NHL
- Ongoing activities in gamma delta therapies for autoimmune disorders
9:30 am ADT3: A Potential First-In-Class EGFR X Vδ1 Bispecific Engager for In Situ Activation of Vδ1 Γδ T Cells And Enhanced Cytotoxicity Towards Solid Tumors
Synopsis
- ADT3 is a bispecific engager that is designed to activate tissue resident VD1 T cells
- ADT3 activates VD1 Gamma delta T cells via crosslinking through EGFR on tumor cells resulting in proliferation, activation and tumor cell killing
- Activation of VD1 cells via ADT3 enables activated Vd1 cells to recognize and kill EGFR positive and EGFR negative tumor cells while sparing EGFR positive healthy cells
10:00 am Morning Refreshments & Networking
Research & Translational Development
Contrasting Approaches in Gamma Delta T Cell Engagers and Cell Therapies
11:00 am Gamma Delta – TIL As Guardians of Epithelia
Synopsis
- Epithelial tissues provide vital barrier and regulatory functions
- Gamma delta T cells stationed within epithelia act as frontline defenders, surveilling for threats and swiftly responding to maintain tissue integrity
- Their sentinel role involves continuous surveillance, rapid response to danger, and facilitation of tissue repair, crucial for overall host defense
11:30 am Biology Guided Design of CAR GD T Cells for the Treatment of Solid Tumors
Synopsis
- Phenotypes of tumor-infiltrating gd T cells: What subsets we need to expand
- Expansion of clinically relevant amounts of gd T cells for treating human solid tumors
- Design of novel CAR architectures optimized for gd T cells
- CAR gd T cells control tumors expressing antigens absent from vital healthy tissues
12:00 pm The Role of gdT Cell Therapies in Autoimmunity
Synopsis
- An alternative to CD19 targeting
- Identifying and removing autoreactive B cells by directlytargeting the B cell activating factor receptors
- Eliminating the cause of inflammation at the source
Clinical Development & Product Optimization
Enhancing Functionality of Gamma Delta T Cells Whilst Preserving Innate Killing Ability
11:00 am Generation of highly active Vδ1 gamma delta T cells from stem cells, for the treatment of haematological and solid tumours
Synopsis
- Differentiation of Vδ1 gamma delta T cells using Notch ligands using cell-based and cell-free systems
- CD1a as a target for T-cell ALL using CAR- Vδ1T-cells
- Advantages versus autologous alphabeta CAR-T cells forT-cell malignancies
11:30 am Round Table: Indication Selection: GDT vs NK vs T Cells
Synopsis
- Consideration of indications where gamma delta T cells exhibit enhanced recognition of stress-induced antigens or phosphoantigens expressed by tumor cells as opposed to NK or alpha beta T cells
- Consideration of indications where gamma delta T cells can effectively target early or advanced-stage solid/liquid tumors over NK or alpha beta T cells
- Potential of introducing combinatory approaches with antibodies/checkpoint inhibitors or other immunomodulators to enhance efficacy
Roundtables are where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. This is a valuable chance for attendees to unite around hot topics and debate best practice. This is a dedicated opportunity for you to voice your experience and identify unique solutions.
12:00 pm Clinical Case Study: Lessons Learned in Phase 1
Synopsis
- A step-by-step guide on preparing and submitting an IND application: Regulatory requirements for IND submission and best practices for engaging with regulatory agencies during the IND filing process
- Sharing lessons learned from being in the clinic, addressing unexpected regulatory challenges in the clinic and incorporating lessons learned into future development strategies
12:30 pm Lunch & Networking
The Role of Gamma Delta T Cells in Autoimmune Diseases
1:30 pm Clinical Data: Bridging Allogeneic CAR-Gamma Delta T Cell to The Clinic
Synopsis
- Tailoring manufacturing platform to expand high-quality engineered gamma delta T products
- Demonstrating preclinical activity of CAR-gamma delta T cells for solid tumors and autoimmune diseases
- Sharing the clinical data of B7H3 CAR-gamma delta T cell therapy for r/r GBM treatment
2:00 pm Fireside Chat: Next Generation GDT Cell Therapy for Autoimmune Disorders
Synopsis
- Exploration of preclinical and clinical evidence supporting the use of gamma delta cell therapies in autoimmune conditions.
- Addressing safety considerations and potential adverse effects associated with gamma delta cell treatments.
- Evaluation of the challenges and opportunities in translating gamma delta cell therapies from bench to bedside for autoimmune diseases.
- Consideration of patient selection criteria and personalized treatment approaches.
- Insights into ongoing research and future directions in the field of gamma delta cell therapy for autoimmune disorders
Regulatory Focus on Allogeneic Off-the- Shelf Gamma Delta T Cell Therapies
1:30 pm Regulatory Overview on Past & Present Gamma Delta T Cell Therapies
Synopsis
- An overview on the current regulatory landscape for allogeneic therapies and discussing any anticipated changes and trends in the regulatory environment for future allogeneic therapies
- Exploration of potential challenges and opportunities in the evolving regulatory landscape and discussing how to use adaptive strategies to address regulatory uncertainties
2:00 pm Audience Led Discussion: Pushing Pipeline into the Clinic
Synopsis
- Establishing a comprehensive understanding of the regulatory landscape for allogeneic off-the-shelf gamma delta T cell therapies
- Covering key aspects such as regulatory considerations for the future, prepping for a BLA, IND filing procedures and overall navigating the journey from IND filing to getting into the clinic
- Open mic for direct questions with industry KOLs
2:30 pm Afternoon Refreshments & Networking
Taking Proactive & Strategic Next Steps in Gamma Delta T Therapy Development
3:00 pm Clinical Potential: GAMMABODY Platform
Synopsis
- Generating bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells
- Complementing natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade
- Demonstrating superior efficacy and safety profiles compared to other bispecific T cell engagers approaches
3:30 pm The Development of Vδ1 Gamma Delta T cell Platforms For Use In Next-Generation Allogeneic CAR Therapies
Synopsis
- Harnessing the potential of γδ T cells for immunotherapy in solid and hematological malignancies
- Investigating the advancements of allogeneic Vδ1 γδ T cell therapy platforms
- Preclinical update on the progress of cell therapy programs utilizing Vδ1 γδ T cells